MedClinic Partners Blog: Compliance & Industry Insights
Compliance & Industry Insights
Expert guidance on 503A/503B compounding regulations, GLP's supply, clinic M&A, and what's changing in medical practice law — written by attorneys and operators who've been in the space.
All Posts
125 articles · Page 1 of 14
Compounding and Mass-Tort Litigation: What Medical Practices Need to Know
Mass-tort litigation against compounding pharmacies and the practices that use them is a real and growing risk. Here is what the litigation landscape looks like and how to protect your practice.
How BUD Is Calculated for Compounded GLP Medications
Beyond-use dates for compounded GLP-1s are not arbitrary. Here is exactly how they are determined under USP 797 and what clinics should ask their pharmacy partners.
GLP's Therapy in Adolescents: What Prescribers Need to Know
GLP's receptor agonists are increasingly being studied and used in adolescents with obesity. Here is what the evidence shows and the regulatory and ethical considerations for prescribers.
NAD+ and the Science of Aging: What Every Prescriber Should Know
NAD+ sits at the intersection of aging biology, metabolism, and cellular repair. Here is a deep dive into the science behind NAD+ and why it has become central to longevity medicine.
BUD vs Expiration Dates: What Every Clinic Must Know
Beyond-use dates and expiration dates are not the same thing. Understanding the difference is critical for clinic compliance and patient safety.
GLP's Drug Interactions: A Prescriber\'s Reference
GLP's receptor agonists have several clinically significant drug interactions. Here is a reference guide for prescribers covering the most important interactions and how to manage them.
Buying a Med Spa or Weight Loss Clinic: Due Diligence Guide
Acquiring a medical aesthetics or weight loss practice requires specialized due diligence. Here is what buyers need to investigate before signing an LOI or closing a deal.
GLP's Therapy: Counseling Patients on Pancreatitis and Thyroid Risk
GLP's receptor agonists carry class warnings for pancreatitis and thyroid C-cell tumors. Here is what the evidence actually shows and how to counsel patients appropriately.
USP <795> and <797> Updates: What Compounders and Practices Need to Know
The United States Pharmacopeia updated its compounding standards in 2023. Here is what changed in USP <795> and <797>, and what the updates mean for practices sourcing compounded medications.